{"id":"placebo-l-dopa","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Nausea"},{"rate":"20-40","effect":"Dyskinesia"},{"rate":"10-20","effect":"Orthostatic hypotension"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Hallucinations"},{"rate":"5-10","effect":"Confusion"},{"rate":"variable with disease duration","effect":"On-off fluctuations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"L-dopa (levodopa) is an amino acid that penetrates the blood-brain barrier more effectively than dopamine itself. Once in the brain, the enzyme aromatic amino acid decarboxylase converts L-dopa to dopamine, restoring neurotransmitter levels in patients with Parkinson's disease where dopamine-producing neurons have degenerated. It is typically co-administered with carbidopa or benserazide (decarboxylase inhibitors) to prevent peripheral conversion and improve central nervous system delivery.","oneSentence":"L-dopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine to replenish depleted dopamine levels in Parkinson's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:09.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease motor symptoms"},{"name":"Restless legs syndrome (off-label)"}]},"trialDetails":[{"nctId":"NCT05909267","phase":"NA","title":"Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2023-07-26","conditions":"Depressive Disorder, Major","enrollment":165},{"nctId":"NCT04469959","phase":"PHASE2","title":"Dopaminergic Dysfunction in Late-Life Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-02-15","conditions":"Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant","enrollment":100},{"nctId":"NCT06075771","phase":"PHASE4","title":"Dopaminergic Therapy for Anhedonia - 2","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-11-21","conditions":"Anhedonia, Depression","enrollment":70},{"nctId":"NCT06954662","phase":"EARLY_PHASE1","title":"A Targeted Amino Acid Supplement for People With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"UConn Health","startDate":"2025-05-22","conditions":"Parkinson Disease, Idiopathic","enrollment":15},{"nctId":"NCT06937307","phase":"PHASE2","title":"Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury","status":"RECRUITING","sponsor":"Giuseppe Cullaro, MD","startDate":"2025-05-27","conditions":"Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver","enrollment":75},{"nctId":"NCT04986982","phase":"PHASE4","title":"OpiCapone Effect on Motor Fluctuations and pAiN","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2021-02-25","conditions":"Parkinson Disease","enrollment":144},{"nctId":"NCT04978597","phase":"PHASE3","title":"Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2021-05-31","conditions":"Parkinson","enrollment":410},{"nctId":"NCT05711082","phase":"NA","title":"REALITY MONITORING","status":"RECRUITING","sponsor":"Hôpital le Vinatier","startDate":"2024-01-15","conditions":"Neurosciences","enrollment":39},{"nctId":"NCT04723147","phase":"PHASE4","title":"DTA (Dopaminergic Therapy for Anhedonia) Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-01-29","conditions":"Depression, Anhedonia","enrollment":19},{"nctId":"NCT03562494","phase":"PHASE1","title":"VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2018-10-17","conditions":"Parkinson's Disease","enrollment":14},{"nctId":"NCT06365515","phase":"NA","title":"Dopamine, Reward Learning and Sex Hormones","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2024-05","conditions":"Hormonal Changes, Menstrual Cycle","enrollment":90},{"nctId":"NCT05148884","phase":"PHASE2","title":"Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia","status":"COMPLETED","sponsor":"Neurolixis SAS","startDate":"2021-11-09","conditions":"Medication-Induced Dyskinesia","enrollment":27},{"nctId":"NCT03881371","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-08-01","conditions":"Parkinson Disease","enrollment":307},{"nctId":"NCT01323374","phase":"PHASE2","title":"Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia","status":"COMPLETED","sponsor":"Chelsea Therapeutics","startDate":"2009-01","conditions":"Fibromyalgia","enrollment":122},{"nctId":"NCT04558112","phase":"PHASE2","title":"Improving Therapeutic Learning for PTSD","status":"UNKNOWN","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-18","conditions":"PTSD, Post Traumatic Stress Disorder","enrollment":120},{"nctId":"NCT03243552","phase":"PHASE2","title":"Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD","status":"UNKNOWN","sponsor":"University of California, Los Angeles","startDate":"2017-06-01","conditions":"ASD","enrollment":56},{"nctId":"NCT03841604","phase":"PHASE4","title":"Effect of Safinamide on Parkinson's Disease Related Chronic Pain","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-04-09","conditions":"Idiopathic Parkinson Disease","enrollment":94},{"nctId":"NCT03761030","phase":"PHASE4","title":"L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2019-01-09","conditions":"Major Depressive Disorder, Dysthymia, Depression","enrollment":51},{"nctId":"NCT04493320","phase":"PHASE4","title":"1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-02-10","conditions":"Depression, Cognitive Impairment, Gait Impairment","enrollment":5},{"nctId":"NCT04650217","phase":"PHASE4","title":"Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-10-07","conditions":"Depressive Disorder","enrollment":1},{"nctId":"NCT04000919","phase":"PHASE2, PHASE3","title":"Effects of 5HTP and LDOPA on CNS Excitability After SCI","status":"SUSPENDED","sponsor":"Jessica M D'Amico","startDate":"2019-06-19","conditions":"Spinal Cord Injuries","enrollment":30},{"nctId":"NCT04764383","phase":"PHASE2","title":"Histaminergic Basis of Fatigue in Multiple Sclerosis","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2022-01-01","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT01951105","phase":"PHASE4","title":"Effect of L-dopa In Subacute Back Pain Population","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-02-24","conditions":"Sub-acute Back Pain","enrollment":72},{"nctId":"NCT01538329","phase":"PHASE2","title":"Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2012-03-04","conditions":"Parkinson Disease","enrollment":210},{"nctId":"NCT01474421","phase":"PHASE2","title":"Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-09-15","conditions":"Dyskinesias, Drug-induced","enrollment":71},{"nctId":"NCT01092065","phase":"PHASE2","title":"Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-03","conditions":"Parkinson's Disease","enrollment":23},{"nctId":"NCT01491529","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Dyskinesias, Parkinson Disease, Movement Disorders","enrollment":154},{"nctId":"NCT01385592","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Dyskinesias, Parkinson Disease, Movement Disorders","enrollment":78},{"nctId":"NCT04173832","phase":"NA","title":"Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2020-01-01","conditions":"L-DOPA-Induced Dyskinesia","enrollment":100},{"nctId":"NCT03541356","phase":"PHASE2","title":"Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal","status":"COMPLETED","sponsor":"Impel Pharmaceuticals","startDate":"2018-05-08","conditions":"Parkinson's Disease","enrollment":32},{"nctId":"NCT01281475","phase":"PHASE2, PHASE3","title":"A Trial of Levodopa in Angelman Syndrome","status":"COMPLETED","sponsor":"Wen-Hann Tan","startDate":"2011-01","conditions":"Angelman Syndrome","enrollment":67},{"nctId":"NCT04082715","phase":"PHASE2","title":"Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity","status":"WITHDRAWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2019-10","conditions":"Chronic Back Pain","enrollment":""},{"nctId":"NCT03754062","phase":"PHASE1","title":"Pharmacological Modulation of Belief Salience","status":"COMPLETED","sponsor":"King's College London","startDate":"2017-06-01","conditions":"Haloperidol, Placebo, L-DOPA","enrollment":30},{"nctId":"NCT02560389","phase":"PHASE4","title":"Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2016-03","conditions":"Stress Disorder, Post Traumatic","enrollment":103},{"nctId":"NCT02873351","phase":"PHASE2","title":"A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration","status":"WITHDRAWN","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2019-09","conditions":"Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT03891095","phase":"NA","title":"Oxytocin and Dopamine's Effect on Vicarious Optimism","status":"COMPLETED","sponsor":"Beijing Normal University","startDate":"2018-12-01","conditions":"Oxytocin Group, L-DOPA Group, Placebo Group","enrollment":156},{"nctId":"NCT02812147","phase":"PHASE2","title":"Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease","status":"UNKNOWN","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2016-05","conditions":"Parkinson Disease","enrollment":20},{"nctId":"NCT01283594","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off","status":"COMPLETED","sponsor":"Biotie Therapies Inc.","startDate":"2011-03","conditions":"Parkinson's Disease","enrollment":420},{"nctId":"NCT00406029","phase":"PHASE2","title":"Dyskinesia in Parkinson's Disease (Study P04501)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11-20","conditions":"Parkinson Disease, Movement Disorders, Central Nervous System Diseases","enrollment":253},{"nctId":"NCT01154166","phase":"PHASE3","title":"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-15","conditions":"Parkinson Disease","enrollment":347},{"nctId":"NCT01494532","phase":"PHASE4","title":"A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-02","conditions":"Parkinson Disease","enrollment":352},{"nctId":"NCT03531060","phase":"PHASE1, PHASE2","title":"A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia","status":"COMPLETED","sponsor":"Integrative Research Laboratories AB","startDate":"2016-11-08","conditions":"Parkinson Disease","enrollment":15},{"nctId":"NCT01176435","phase":"PHASE2","title":"Trial of L-DOPA as a Treatment to Improve Vision in Albinism","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2010-09","conditions":"Albinism","enrollment":45},{"nctId":"NCT01646255","phase":"PHASE3","title":"Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-07","conditions":"Idiopathic Parkinson's Disease","enrollment":346},{"nctId":"NCT00634556","phase":"PHASE1","title":"Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2006-02","conditions":"Tourette Syndrome","enrollment":49},{"nctId":"NCT03333369","phase":"EARLY_PHASE1","title":"Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2014-05-15","conditions":"Healthy, Schizotypal Personality","enrollment":65},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT00381472","phase":"PHASE3","title":"Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Parkinson Disease","enrollment":393},{"nctId":"NCT00986414","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-09","conditions":"Parkinson Disease, Dyskinesias","enrollment":260},{"nctId":"NCT01504178","phase":"PHASE3","title":"Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2011-05","conditions":"Parkinson's Disease","enrollment":28},{"nctId":"NCT01602549","phase":"PHASE2","title":"A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07","conditions":"Gastroparesis","enrollment":58},{"nctId":"NCT02807675","phase":"PHASE1","title":"A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2016-06","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT00314288","phase":"PHASE2","title":"Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2002-07","conditions":"Parkinson's Disease, Dyskinesia","enrollment":360},{"nctId":"NCT02999581","phase":"NA","title":"Effects of a Pre-Workout Dietary Supplement on Training Adaptations","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2014-03","conditions":"Dietary Modification","enrollment":122},{"nctId":"NCT02952014","phase":"NA","title":"Assessment of a Pre-Workout Dietary Supplement","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2014-02","conditions":"Dietary Modification","enrollment":31},{"nctId":"NCT02633007","phase":"PHASE1","title":"A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2015-12","conditions":"Asthma","enrollment":25},{"nctId":"NCT00888004","phase":"PHASE2","title":"Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Parkinson's Disease, L-dopa Induced Dyskinesia","enrollment":28},{"nctId":"NCT01227655","phase":"PHASE3","title":"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2011-03","conditions":"Parkinson's Disease","enrollment":427},{"nctId":"NCT01568073","phase":"PHASE3","title":"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With \"Wearing-off\" Phenomenon","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2011-03","conditions":"Parkinson's Disease","enrollment":600},{"nctId":"NCT00560508","phase":"PHASE2, PHASE3","title":"A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-11","conditions":"Parkinson Disease","enrollment":112},{"nctId":"NCT00547911","phase":"PHASE1, PHASE2","title":"Augmenting Effects of L-DOPS With Carbidopa and Entacapone","status":"TERMINATED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2007-10","conditions":"Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases","enrollment":14},{"nctId":"NCT00466167","phase":"PHASE3","title":"Pivotal Study in Advanced Parkinsons Disease Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-04","conditions":"Parkinson Disease","enrollment":517},{"nctId":"NCT02172573","phase":"PHASE3","title":"Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-04","conditions":"Parkinson Disease","enrollment":315},{"nctId":"NCT01628926","phase":"PHASE3","title":"A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-06","conditions":"Parkinson's Disease","enrollment":420},{"nctId":"NCT00537485","phase":"PHASE2, PHASE3","title":"A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-09","conditions":"Early Parkinson's Disease","enrollment":180},{"nctId":"NCT01628848","phase":"PHASE2","title":"A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2006-08","conditions":"Parkinson's Disease","enrollment":174},{"nctId":"NCT01113320","phase":"PHASE2","title":"Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2010-04","conditions":"Parkinson's Disease","enrollment":26},{"nctId":"NCT00224263","phase":"PHASE2","title":"Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2005-09","conditions":"Parkinson's Disease","enrollment":360},{"nctId":"NCT01361373","phase":"PHASE4","title":"Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study","status":"UNKNOWN","sponsor":"Shaare Zedek Medical Center","startDate":"2010-05","conditions":"Dystonic Cerebral Palsy","enrollment":50},{"nctId":"NCT00582673","phase":"PHASE2","title":"Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Parkinson's Disease","enrollment":31},{"nctId":"NCT00373087","phase":"PHASE4","title":"COMT Polymorphism and Entacapone Efficacy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":60},{"nctId":"NCT00134251","phase":"PHASE3","title":"Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2005-10","conditions":"Parkinson's Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo/L-dopa","genericName":"placebo/L-dopa","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-dopa is used to treat conditions such as Parkinson Disease, Movement Disorders, and Neurodegenerative Diseases, as indicated by ClinicalTrials.gov. Placebo is used as a control in studies comparing its effects to those of L-dopa, such as in the study \"Dyskinesia in Parkinson's Disease (Study P04501)\" on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}